Lineage to Host Virtual OPC1 Investor & Analyst Day on February 22, 2021
February 16 2021 - 8:00AM
Business Wire
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX),
a clinical-stage biotechnology company developing allogeneic cell
therapies for unmet medical needs, today announced it will be
hosting a virtual Investor and Analyst Day on February 22, 2021 at
1:30pm PT / 4:30pm ET to discuss the company’s OPC1 program for
acute spinal cord injury. Lineage management will be joined by
therapeutic area expert Edward Wirth, III, M.D., Ph.D., for an
update on OPC1, an oligodendrocyte progenitor cell (OPC) transplant
designed to provide clinically meaningful improvements in motor
recovery for individuals with acute spinal cord injuries (SCI). The
OPC1 program has been partially funded by a $14.3 million grant
from the California Institute for Regenerative Medicine (CIRM) and
has received Regenerative Medicine Advanced Therapy (RMAT)
designation and Orphan Drug designation from the U.S. Food and Drug
Administration. Jason McCarthy, Ph.D., Senior Managing Director,
Biotechnology, Maxim Group, LLC will moderate the event and
interested parties can register for the event directly on the
Solebury Trout Events Page.
Interested investors can access the live webcast on the Events
and Presentations section of Lineage’s website. Additional videos
are available on the Media page of the Lineage website.
“We are fortunate to have Dr. Wirth available to review the
clinical data collected to date and discuss the opportunity to use
oligodendrocyte progenitor cell transplants to aid recovery
following a severe spinal cord injury. Dr. Wirth also will discuss
our recently announced partnership with Neurgain Technologies, Inc.
to evaluate an improved delivery system designed to allow for more
precise administration of cells with shorter cessation of a
patient’s respiration,” stated Brian Culley, CEO. “Ed has broad
experience with the development of cell-based therapies for spinal
cord injury and neurological disorders and notably, led the team
which conducted the first human pluripotent stem cell spinal cord
transplant in the United States.”
Therapeutic Expert: Edward Wirth, III, M.D.,
Ph.D.
Dr. Wirth currently serves as the Chief Medical Officer at Aspen
Neuroscience, Inc., a company working to develop best-in-class
autologous cell therapies for neurological diseases such as
Parkinson disease. Dr. Wirth’s specialties include clinical trials,
translational research, stem cells, cell-based therapies, magnetic
resonance imaging, spinal cord injury and neurological
disorders.
Dr. Edward Wirth completed the M.D./Ph.D. program at the
University of Florida (UF) in 1994. He elected to remain at UF to
conduct postdoctoral research and subsequently joined the faculty
in 1996. From 1997 to 2002, Dr. Wirth led the UF team that
performed the first human pluripotent stem cell spinal cord
transplant in the United States. This study demonstrated the
feasibility and safety of implanting cell line-derived spinal cord
cells into patients with post-traumatic syringomyelia (a
complication of spinal cord injury). From 2002 to 2004, Dr. Wirth
held academic appointments at Rush Presbyterian St. Luke’s Medical
Center and at the University of Chicago. From 2004 to 2011, he
served as Medical Director for Regenerative Medicine at Geron
Corporation, where he led the world’s first clinical trial of a
hESC-derived transplant. In 2013 he joined Asterias Biotherapeutics
and served as its Chief Translational Officer from 2013 to 2015 and
Chief Medical Officer from 2015 to 2019. At Asterias, Dr. Wirth led
the expansion and completion of the clinical trial which
demonstrated the initial clinical safety and activity of OPC1 in
patients with subacute spinal cord injuries. He briefly served as
Chief Medical Officer of Lineage Cell Therapeutics, which acquired
Asterias in March 2019, before joining Aspen Neuroscience as its
Chief Medical Officer.
About Spinal Cord Injuries
A spinal cord injury (SCI) occurs when the spinal cord is
subjected to a severe crush or contusion and frequently results in
severe functional impairment, including limb paralysis, aberrant
pain signaling, and loss of bladder control and other body
functions. There are approximately 18,000 new spinal cord injuries
annually in the U.S. There are no FDA-approved drugs specifically
for the treatment of SCI. The cost of a lifetime of care for a
severe spinal cord injury can be as high as $5 million.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology
company developing novel cell therapies for unmet medical needs.
Lineage’s programs are based on its robust proprietary cell-based
therapy platform and associated in-house development and
manufacturing capabilities. With this platform Lineage develops and
manufactures specialized, terminally differentiated human cells
from its pluripotent and progenitor cell starting materials. These
differentiated cells are developed to either replace or support
cells that are dysfunctional or absent due to degenerative disease
or traumatic injury or administered as a means of helping the body
mount an effective immune response to cancer. Lineage’s clinical
programs are in markets with billion dollar opportunities and
include three allogeneic (“off-the-shelf”) product candidates: (i)
OpRegen®, a retinal pigment epithelium transplant therapy in Phase
1/2a development for the treatment of dry age-related macular
degeneration, a leading cause of blindness in the developed world;
(ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a
development for the treatment of acute spinal cord injuries; and
(iii) VAC, an allogeneic dendritic cell therapy platform for
immuno-oncology and infectious disease, currently in clinical
development for the treatment of non-small cell lung cancer. For
more information, please visit www.lineagecell.com or follow the
Company on Twitter @LineageCell.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210216005120/en/
Lineage Cell Therapeutics, Inc. IR Ioana C. Hone
(ir@lineagecell.com) (442) 287-8963
Solebury Trout IR Gitanjali Jain Ogawa
(Gogawa@troutgroup.com) (646) 378-2949
Russo Partners – Media Relations Nic Johnson or David
Schull Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com (212) 845-4242
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Apr 2023 to Apr 2024